Fresenius SE / Final Results 19.02.2009 Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Successful 2008 − Financial targets fully met or exceeded − Positive outlook for 2009 Group sales increased by 13 % in constant currency and by 9 % at actual rates to EUR 12,336 million (2007: EUR 11,358 million). Organic sales growth was 8 %. Acquisitions contributed a further 5 %, mainly driven by the consolidation of APP Pharmaceuticals as from September 1, 2008. Currency translation had a negative impact of 4 %. The Group's US GAAP annual financial results as of December 31, 2008 include special items relating to the acquisition of APP Pharmaceuticals. The single-largest of those items is the full depreciation of acquired in-process R&D activities. Adjusted earnings represent the Group's business operations in the reporting period. Adjusted Group operating income (EBIT, before special items) grew by 11 % in constant currency and by 7 % at actual rates to EUR 1,727 million (2007: EUR 1,609 million). Group EBIT (including special items) was EUR 1,477 million. Adjusted Group net income grew by 13 % in constant currency and by 10 % at actual rates to EUR 450 million (2007: EUR 410 million). Adjusted earnings per ordinary share increased to EUR 2.85 and adjusted earnings per preference share increased to EUR 2.86 (2007: ordinary share EUR 2.64, preference share EUR 2.65). This represents an increase of 11 % for both share classes in constant currency. Group net income (including special items) was EUR 270 million or EUR 1.71 per ordinary share and EUR 1.72 per preference share. The Management Board will propose to the Supervisory Board a dividend increase to EUR 0.70 per ordinary share (2007: EUR 0.66) and to EUR 0.71 per preference share (2007: EUR 0.67) for fiscal year 2008. For 2009, Fresenius projects further improvements in its financial results: Group sales are expected to grow by more than 10 % in constant currency. Organic growth is projected to be in a 6 to 8 % range. Adjusted net income (before special items) is expected to increase by aproximately 10 % in constant currency. The special items relate to the mark-to-market accounting of both the mandatory exchangeable bond (MEB) and the contingent value right (CVR) and are not cash relevant. (Financial statements according to US GAAP) The Management Board Bad Homburg v.d.H., February 19, 2009 End of note DGAP 19.02.2009 --------------------------------------------------------------------------- Language: English Issuer: Fresenius SE Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Deutschland Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: ir-fre@fresenius.com Internet: www.fresenius.com ISIN: DE0005785638, DE0005785604 WKN: 578563, 578560 Indices: MDAX Listed: Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf, München; Freiverkehr in Berlin, Hannover, Stuttgart, Hamburg; Terminbörse EUREX End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Fresenius SE:Successful 2008 − Financial targets fully met or exceeded − Positive outlook for 2009
| Source: EQS Group AG